Six end-stage renal disease patients benefited from first non-simultaneous single center 6-way kidney exchange transplantation in India

doi:10.5527/wjn.v5.i6.531

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9504)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

396

WORD

364

HTML

3511

Figures (1-1)

329

Tables (1-5)

442

Sum=5042

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

825

Download

1472

Sum=2297

Publishing Process of This Article

Item

Count

Browse

916

Download

1249

Sum=2165

Nov 6, 2016 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Nephrol. Nov 6, 2016; 5(6): 531-537
Published online Nov 6, 2016. doi: 10.5527/wjn.v5.i6.531

Table 2 Desensitisation protocol and outcome

	Patient 1	Patient 2	Patient 3
Before desensitization with original donor
LCM/DTT/AHG (%)	80/80/90	5/5/7	5/0/5
T/B FCM (MCS)	260/298	Neg/236	80/159
DSA class 1	A1 = 8000, B57 = 6200	No DSA	B44 = 4188, A31 1100
DSA class 2	DQ7 = 1600, DQ9 = 2200	DQ2 = 9000	No DSA
DP	8TPE + 8Bort/MP/IVIG + TAC/MMF	9TPE + 6Bort/MP/IVIG + R + TAC/MMF	4TPE + 4Bort/MP/IVIG + TAC/MMF
After desensitization with original donor
LCM	80/80/90	17/15/20	5/0/7
FCM	254/333	Neg/504	Neg/129
DSA class 1	A1 = 2000, B57 = 5500	No DSA	B44 = 4622, A31 = 1400
DSA class 2	DQ7 = 2000, DQ9 = 2000	DQ2 = 12000	No DSA
Side effects	Tuberculosis	Graft nephrectomy	Tuberculosis

TPE: Plasmapheresis; Bort: Bortezomib; MP: Methyl prednisolone; IVIG: Immunoglobulin; R: Rituximab; TAC: Tacrolimus; MMF: Mycophenolate mofetyl; DP: Desensitization protocol; LCM: Lymphocyte cross match; FCM: Flow cross match; DSA: Donor specific antibody; Neg: Negative; MCS: Median channel shift; DTT: Dithiothreitol; AHG: Antihuman globulin test.

Citation: Kute VB, Patel HV, Varyani UT, Shah PR, Modi PR, Shah VR, Rizvi SJ, Pal BC, Shah PS, Wakhare PS, Ghodela VA, Shinde SG, Trivedi VB, Patel MH, Trivedi HL. Six end-stage renal disease patients benefited from first non-simultaneous single center 6-way kidney exchange transplantation in India. World J Nephrol 2016; 5(6): 531-537
URL: https://www.wjgnet.com/2220-6124/full/v5/i6/531.htm
DOI: https://dx.doi.org/10.5527/wjn.v5.i6.531